ArticleFrontiers in bioengineering and biotechnology2026
Evaluation of tissue-engineered blood vessels as three-dimensional in vitro testing system in cardiovascular research.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Disturbed crosstalk between endothelial cells (ECs) and vascular smooth muscle cells (SMCs) has an important role in intimal hyperplasia and restenosis after vascular interventions, however, the exact pathomechanisms are incompletely understood. Current preclinical models inadequately recapitulate the complexity of human arteries. Objective: We present tissue-engineered blood vessels (TEBVs) as a novel Methods: TEBVs fabricated from SMC suspended in fibrin gel, supported by a textile mesh, were seeded with ECs at various concentrations and subjected to arterial flow conditions in a bioreactor for 21 days. In addition, TEBVs underwent plain old balloon angioplasty (POBA) and implantation of bare metal stents (BMS) and drug-eluting stents (DES) at day 7 after fabrication. TEBVs were monitored by optical coherence tomography. Results: TEBVs with absent or incomplete endothelial layer exhibited thicker vessel walls, more disorganized collagen. Quantitative analysis of Ki67 and αSMA revealed no statistically significant differences in SMC proliferation or contractile phenotype across varying degrees of endothelial coverage. POBA and stent implantation were feasible at day 7. 14 days post-intervention, POBA-treated TEBVs exhibited significantly thicker vessel walls than untreated controls and stented TEBVs, whereas stented TEBVs showed greater lumen diameters than unstented TEBVs. Endothelial coverage was higher in BMS than DES. Levels of IL-6, IL-8, and MCP-1 were highest in medium from BMS-treated TEBVs. Conclusion: TEBVs provide a promising
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.